Skip to Content

Clinical Trial News

This section provides information about recently completed clinical trials. If you cannot find information about a particular clinical trial, you should note that results may not be available even after the trial ends. Some trials end before completion and results are never published.

Novo Nordisk to Initiate Phase 3a Development of Oral Semaglutide, a Once-Daily Oral GLP-1 Analogue

Posted 4 days ago in Clinical Trials

Bagsværd, Denmark, 26 August 2015 - Novo Nordisk today announced the decision to initiate a phase 3a programme with oral semaglutide; a once-daily oral formulation of the long-acting GLP-1 analogue semaglutide. The decision follows the encouraging results of the proof-of-concept phase 2 trial announced on 20 February 2015 and the subsequent consultations with regulatory authorities. Novo Nordisk intends to...

Read more...

GSK Announces NEJM Publication of Phase 3b/4 Study of Ambrisentan and Tadalafil as First-Line Combination Treatment in Patients with Pulmonary Arterial Hypertension

Posted 4 days ago in Clinical Trials

London, UK -- 26 August 2015 -- GSK today announced publication of the AMBITION study, the first outcomes study to compare the safety and efficacy of investigational first-line combination therapy of Volibris® (ambrisentan) and Adcirca® (tadalafil) to first-line monotherapy of either treatment alone in treatment-naïve patients with pulmonary arterial hypertension (PAH). The AMBITION study was a randomised,...

Read more...

Syndax Enters Clinical Trial Collaboration In Cancer Immunotherapy Combining Entinostat and Atezolizumab

Posted 4 days ago in Clinical Trials

WALTHAM, Mass., August 26, 2015 – Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing entinostat as a combination therapy in multiple cancer indications, announced today that it has entered into a clinical collaboration with Genentech, a member of the Roche Group, to evaluate the safety, tolerability and preliminary efficacy of Syndax’s entinostat, an oral small...

Read more...

Corium Initiates Phase 1 Clinical Trial of Corplex Donepezil Transdermal System for the Treatment of Alzheimer's Disease

Posted 5 days ago in Clinical Trials

MENLO PARK, Calif., Aug. 25, 2015 (GLOBE NEWSWIRE) -- Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced the commencement of dosing in a Phase 1 clinical trial to evaluate the safety, pharmacokinetics and pharmacodynamics of Corplex™ Donepezil Transdermal System for...

Read more...

AstraZeneca and Peregrine Pharmaceuticals to Collaborate on Immuno-Oncology Combination Clinical Trial

Posted 6 days ago in Clinical Trials

Monday, 24 August 2015 -- AstraZeneca today announced that it has entered into a clinical trial collaboration with Peregrine Pharmaceuticals, Inc. to evaluate the safety and efficacy of Peregrine’s investigational phosphatidylserine (PS)-signalling pathway inhibitor, bavituximab, in combination with AstraZeneca’s investigational anti-PD-L1 immune checkpoint inhibitor, durvalumab (MEDI4736). The planned Phase...

Read more...

Pivotal Phase II Study Showed Atezolizumab Shrank Tumors in People with a Specific Type of Lung Cancer

Posted 2 weeks ago in Clinical Trials

South San Francisco, CA -- August 16, 2015 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that in the large pivotal Phase II study, BIRCH, the investigational cancer immunotherapy atezolizumab (MPDL3280A; anti-PDL1) met its primary endpoint and shrank tumors (objective response rate; ORR) in people with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose...

Read more...

Pivotal Phase II Study of Investigational Medicine Venetoclax Met Primary Endpoint in a Hard-To-Treat Type of Chronic Lymphocytic Leukemia

Posted 2 weeks ago in Clinical Trials

South San Francisco, CA -- August 12, 2015 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced positive results today from the Phase II M13-982 study of venetoclax, an investigational medicine being developed in partnership with AbbVie. The study met its primary endpoint, showing that venetoclax monotherapy resulted in a clinically meaningful reduction in the number of cancer cells...

Read more...

UCSF To Study Halozyme PEGPH20 In Pancreatic Cancer Patients Who Are Candidates For Potentially Curative Surgery

Posted 3 weeks ago in Clinical Trials

SAN DIEGO, Aug. 6, 2015 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) today announced the Pancreas Center at the University of California, San Francisco (UCSF) has initiated a clinical research study of Halozyme's investigational new drug, PEGPH20 in pancreatic cancer patients who are candidates for potentially curative surgery. The trial will be conducted within the UCSF Helen Diller Family...

Read more...

Cipher Pharmaceuticals Announces Successful Completion of Second Phase III for Ozenoxacin

Posted 3 weeks ago in Clinical Trials

MISSISSAUGA, ON, July 30, 2015 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that Ferrer International SA ("Ferrer") successfully completed the second phase III clinical trial for Ozenoxacin, a topical treatment for adult and paediatric patients with impetigo, a highly contagious bacterial skin infection. Cipher acquired the Canadian commercialization rights...

Read more...

Vaccine Candidate Potentially Effective Against Ebola in Large Trial in Guinea

Posted 4 weeks ago in Clinical Trials

AMES, Iowa, July 31, 2015 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that the international partnership studying the VSV-ZEBOV (Ebola) vaccine candidate in Guinea has released interim data suggesting that it is effective against Ebola in a large clinical trial. According to the announcement, the interim results suggest that the vaccine candidate demonstrates efficacy within about...

Read more...

KaloBios Announces FDA Clearance of Investigational New Drug Application for KB003 in Patients with Chronic Myelomonocytic Leukemia

Posted 4 weeks ago in Clinical Trials

SOUTH SAN FRANCISCO, July 29, 2015 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO), a monoclonal antibody company focused on developing innovative therapies to benefit patients with diseases of unmet medical need, with a focus on oncology, announced today that the U.S. Food and Drug Administration (FDA) has cleared the company's investigational new drug (IND) application for KB003, an anti-GM-CSF...

Read more...

Sanofi Announces That First LixiLan Phase III Study Met Primary Endpoint

Posted 4 weeks ago in Clinical Trials

PARIS, July 29, 2015 /PRNewswire/ -- Sanofi announced today that the LixiLan-O Phase III clinical trial met its primary objective in patients with type 2 diabetes treated with metformin. The fixed-ratio combination of insulin glargine 100 units/mL and lixisenatide, a GLP-1 RA, demonstrated statistically superior reduction in HbA1c (average blood glucose over the previous three months) compared with lixisenatide and...

Read more...

Ignyta Announces FDA Clearance of IND for RXDX-107

Posted 4 weeks ago in Clinical Trials

SAN DIEGO, July 29, 2015 --(BUSINESS WIRE)-- Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug application (IND) for Ignyta's new chemical entity RXDX-107, a next-generation alkyl ester of bendamustine encapsulated in human serum albumin (HSA) to form nanoparticles. Under this IND, the...

Read more...

Lilly Provides Update On Evacetrapib Phase 3 Trial

Posted 4 weeks ago in Clinical Trials

INDIANAPOLIS, July 27, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) has accepted the recommendation of the ACCELERATE study data monitoring committee to continue the Phase 3 trial of the investigational medicine evacetrapib, based on data from an interim futility analysis. Last patient visit in ACCELERATE – which is evaluating evacetrapib in approximately 12,000 patients with high-risk atherosclerotic...

Read more...

Lpath Announces Plan to Begin Lpathomab Clinical Trial

Posted 5 weeks ago in Clinical Trials

SAN DIEGO, July 23, 2015 /PRNewswire/ -- Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, announced that the U.S. Food and Drug Administration (FDA) has completed its review of the Investigational New Drug Application (IND) for Lpathomab™. The FDA informed the company that the Phase 1 clinical trial to study Lpathomab may now be initiated. Lpath plans to begin this trial...

Read more...

Sunesis Pharmaceuticals Announces Regulatory Update for Qinprezo (vosaroxin)

Posted 5 weeks ago in Clinical Trials

SOUTH SAN FRANCISCO, Calif., July 23, 2015 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced regulatory updates from its interactions with the European Medicines Agency (EMA) and U.S. Food and Drug Administration (FDA) regarding a potential path toward marketing authorization for vosaroxin as a treatment for acute myeloid leukemia (AML) in Europe and the United States. With respect...

Read more...

AstraZeneca Provides Update on Selumetinib in Uveal Melanoma

Posted 5 weeks ago in Clinical Trials

Wednesday, 22 July 2015 -- AstraZeneca today announced that the Phase III SUMIT study of selumetinib in combination with dacarbazine for the treatment of patients with metastatic uveal melanoma did not meet its primary endpoint of progression free survival. This combination therapy showed an adverse event profile generally consistent with current knowledge of the safety profiles of dacarbazine and selumetinib. A...

Read more...

Data Using New Delayed-Start Methodology Suggested Benefit Of Early Treatment With Solanezumab In Patients With Mild Alzheimer's Disease

Posted 5 weeks ago in Clinical Trials

INDIANAPOLIS, July 22, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced results suggesting the treatment effect of solanezumab was preserved within a pre-specified amount in patients with mild Alzheimer's disease who received solanezumab earlier in the disease compared to patients who began treatment at a later point. These results were from a pre-specified secondary analysis of the Phase 3...

Read more...

BMS Receives FDA Breakthrough Therapy Designation for Investigational HIV-1 Attachment Inhibitor

Posted 5 weeks ago in Clinical Trials

PRINCETON, N.J., July 21, 2015 --(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to the investigational compound BMS-663068 when used in combination with other antiretroviral (ARV) agents for the treatment of HIV-1 infection in heavily treatment-experienced adult patients. BMS-663068 is an oral...

Read more...

Cytokinetics Announces Start of Phase 3 Clinical Trial of Tirasemtiv in Patients with ALS

Posted 6 weeks ago in Clinical Trials

South San Francisco, CA - July 14, 2015 -- Cytokinetics, Inc. (Nasdaq: CYTK), a leading muscle biology company, today announced the start of VITALITY-ALS (Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices after Treatment for a Year in ALS), a Phase 3 clinical trial designed to assess the effects of tirasemtiv versus placebo on slow vital capacity (SVC) and other measures of respiratory...

Read more...
Older articles
Hide